Biotech’s slump may finally be over in 2026. In interviews with BioSpace, Zymeworks’ CEO Ken Galbraith and Zai Lab’s ...

South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...

Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...

Turning the tide on antibiotic resistance will require new ways of working, writes executive director of the Global ...

Innovation drives speed in early phase drug development. ICON’s Accelerated Pharmaceutical Solutions integrate advanced ...

BOSTON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- BPGbio, Inc., a biology-first, AI-powered, clinical-stage biopharma focused on mitochondrial biology and protein homeostasis, today announced it has won the ...

Insmed is discontinuing its development of brensocatib after a Phase 2b study found that the chronic rhinosinusitis treatment failed to meet its primary or secondary efficacy endpoints.

America, since the conclusion of World War II, has dominated the R&D pipeline. Past research from our team at the Center for ...

The pharmaceutical industry is experiencing its own “DeepSeek moment,” according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as ...

The volatile biotech industry has put up a strong performance in 2025 despite the uncertain macroeconomic environment. While ...

Dec 12 () - The weight-loss drug market is booming, with biotech firms racing to secure their place in a lucrative sector ...

Philadelphia has lagged in biotech R&D jobs despite University of Pennsylvania scientists playing a leading role in ...